angiotensin IV raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-10. Anything still debated is marked as such rather than presented as settled.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
The first symptoms of apitoxin (bee venom), that are now thought to be caused by apamin, were described back in 1936 by Hahn and Leditschke. Apamin was first isolated by Habermann in 1965 from Apis mellifera, the Western honey bee. Apamin was named after this bee. Bee venom contains many other compounds, like histamine, phospholipase A2, hyaluronidase, MCD peptide, and the main active component melittin. Apamin was separated from the other compounds by gel filtration and ion exchange chromatography.
Neptunium nitride (NpN) was first prepared in 1953 by reacting neptunium hydride and ammonia gas at around 750 °C in a quartz capillary tube. Later, it was produced by reacting different mixtures of nitrogen and hydrogen with neptunium metal at various temperatures. It has also been produced by the reduction of neptunium dioxide with diatomic nitrogen gas at 1550 °C. NpN is isomorphous with uranium mononitride (UN) and plutonium mononitride (PuN) and has a melting point of 2830 °C under a nitrogen pressure of around 1 MPa. Two neptunium phosphide compounds have been reported, NpP and Np3P4. The first has a face centered cubic structure and is prepared by converting neptunium metal to a powder and then reacting it with phosphine gas at 350 °C. Np3P4 can be produced by reacting neptunium metal with red phosphorus at 740 °C in a vacuum and then allowing any extra phosphorus to sublimate away. The compound is non-reactive with water but will react with nitric acid to produce Np(IV) solution. Three neptunium arsenide compounds have been prepared, NpAs, NpAs2, and Np3As4. The first two were first produced by heating arsenic and neptunium hydride in a vacuum-sealed tube for about a week. Later, NpAs was also made by confining neptunium metal and arsenic in a vacuum tube, separating them with a quartz membrane, and heating them to just below neptunium's melting point of 639 °C, which is slightly higher than the arsenic's sublimation point of 615 °C. Np3As4 is prepared by a similar procedure using iodine as a transporting agent. NpAs2 crystals are brownish gold and Np3As4 is black.
The thiazolidinediones , abbreviated as TZD, also known as glitazones after the prototypical drug ciglitazone, are a class of heterocyclic compounds consisting of a five-membered C3NS ring. The term usually refers to a family of drugs used in the treatment of diabetes mellitus type 2 that were introduced in the late 1990s. As of 2024, there are two FDA-approved drugs in this class, pioglitazone and rosiglitazone.
=== Abiotic synthesis === The widespread utilization of PLP in central metabolism, especially in amino acid biosynthesis, and its activity in the absence of enzymes, suggests PLP may be a "prebiotic" compound—that is, one that predates the origin of organic life (not to be confused with prebiotic compounds, substances which serve as a food source for beneficial bacteria). In fact, heating NH3 and Glycolaldehyde spontaneously forms a variety of pyridines, including pyridoxal. Under certain conditions, PLP is formed from cyanoacetylene, diacetylene, carbon monoxide, hydrogen, water, and a phosphoric acid.
The shortage of manufacturing facilities for the Il-86 was a problem from the outset: "The rapid modernisation of the Soviet Air Force ... has left limited scope for the expansion of commercial production ... the lack of production capacity is being remedied partly by ... international cooperation." This meant involving the Polish aircraft industry in the project.
Sources: en.wikipedia.org
Surface-supplied diving equipment (SSDE) is the equipment required for surface-supplied diving. The essential aspect of surface-supplied diving is that breathing gas is supplied from the surface, either from a specialised diving compressor, high-pressure gas storage cylinders, or both. In commercial and military surface-supplied diving, a backup source of surface-supplied breathing gas should always be present in case the primary supply fails. The diver may also wear a bailout cylinder (emergency gas supply) which can provide self-contained breathing gas in an emergency. Thus, the surface-supplied diver is less likely to have an "out-of-air" emergency than a scuba diver using a single gas supply, as there are normally two alternative breathing gas sources available. Surface-supplied diving equipment usually includes communication capability with the surface, which improves the safety and efficiency of the working diver. The equipment needed for surface supplied diving can be broadly grouped as diving and support equipment, but the distinction is not always clear. Diving support equipment is equipment used to facilitate a diving operation. It is either not taken into the water during the dive, such as the gas panel and compressor, or is not integral to the actual diving, being there to make the dive easier or safer, such as a surface decompression chamber. Some equipment, like a diving stage, is not easily categorised as diving or support equipment, and may be considered as either.
Nuevas Ideas retained its Legislative Assembly supermajority and, with its allies, won 43 of the country's 44 municipalities. Several news outlets described the election results as a "landslide victory" for Bukele and Nuevas Ideas, and Bukele described his victory as "the record in the entire democratic history of the world". The TSE granted Bukele his presidential credentials on 29 February and his second term began on 1 June. In a 2024 interview with Time, Bukele declined to run for a third term in the next presidential election. In July 2025, the Legislative Assembly passed several constitutional amendments, among them, the abolition of presidential term limits that made Bukele eligible to run for re-election indefinitely. Additionally, the legislature voted to move the date of the next presidential election from 2029 to 2027, reducing the length of Bukele's second term by two years. In December 2025, Bukele told YouTuber TheGrefg that "if it were up to me, I would stay for 10 more years". On 28 June 2026, Bukele registered as a pre-candidate with Nuevas Ideas, seeking a third presidential term; on 12 July, the party formally nominated him as its presidential candidate.
Acebutolol, sold under the brand names Sectral among others, is a beta blocker for the treatment of hypertension and arrhythmias. Acebutolol is a cardioselective beta-1 blocker and has intrinsic sympathetic activity. It is commonly used in the treatment of angina. It was patented in 1967 and approved for medical use in 1973.
They built on the character of the Aperture Science facility, providing a deeper story for GLaDOS and Aperture's CEO Cave Johnson, as well as developing several concepts for "personality cores" that ultimately led to the creation of Wheatley. Portal 2 received similar acclaim to its predecessor at launch, garnering a Metacritic score of 95 out of 100. Valve has continued to support the game through the release of two separate downloadable content packages, one introducing a new co-operative campaign, and a second that incorporated an easy-to-learn level editor that allowed players to make their own test chambers and share these through the Steam Workshop to others. An alternate version of Portal 2 designed for educational use was developed for Valve's Steam for Schools program, and was made available for free. While experimenting with VR systems in 2017, Valve attempted to implement Portal-like gameplay, but early playtesters found the game's titular mechanic disorienting in VR. Valve instead returned to the Half-Life series and released Half-Life: Alyx in 2020. In April 2022, Erik Wolpaw urged Valve to make Portal 3, saying, "I am... not getting any younger. We are reaching the point where – it's crazy to think – [we're] literally going to be too old to work on Portal 3. So we should just do it." In September, Ellen McLain also called for Portal 3, stating that she was willing to star in it, and asked fans to "write in. Email Valve. You've got my blessing".
== External links == Clinical trial number NCT05662332 for "A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) (QWINT-1)" at ClinicalTrials.gov Clinical trial number NCT05362058 for "A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-2)" at ClinicalTrials.gov Clinical trial number NCT05275400 for "A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin" at ClinicalTrials.gov Clinical trial number NCT05462756 for "A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections (QWINT-4)" at ClinicalTrials.gov
Sources: en.wikipedia.org
Osteoclasts are located on the surface of bones and form resorption pits by excreting H+ to the bone surface removing hydroxyapatite, multiple bone minerals, and organic components: collagen and dentin. The purpose of bone resorption is to release calcium to the blood stream for various life processes. These resorption pits are visible under electron microscopy and distinctive trails are formed from prolonged resorption. Osteoclasts have shown to be "absolutely dependent on extracellular acidification". A drop in pH of <0.1 units can cause a 100% increase in osteoclast cell activity, this effect persists with prolonged acidosis with no desensitization, "amplifying the effects of modest pH differences". Osteoclast cells show little or no activity at pH 7.4 and are most active at pH 6.8 but can be further stimulated by other factors such as parathyroid hormone.
On the morning of 8 September, representatives of the Fatherland Front - Kimon Georgiev, Nikola Petkov, Dimitar Neykov, Kiril Dramaliev and Dimo Kazasov - met with the Prime Minister, protesting the dispersal of opposition demonstrations in the previous days and demanding that rallies be allowed in the major cities. Kimon Georgiev hosted a meeting of the Fatherland Front's National Committee at 4 p.m. on 8 September. The government's composition was settled upon, and its policy text is approved. The composition of the future government and the new regents were specified at a meeting between Kimon Georgiev, Dobri Terpeshev, Nikola Petkov and Damyan Velchev at Georgiev's home at 4 pm on 8 September. It was agreed that the cabinet would include four representatives each of the BRP, Zveno and BZNS-Pladne, two of the BRSD and two independents, and that the prime minister would be Kimon Georgiev, a decision agreed with Soviet dictator Joseph Stalin. Georgiev spent the night of the coup with Damyan Velchev, Nikola Petkov, and Traicho Dobroslavsky at the home of Yanko Antonov near the Eagles Bridge - he was a neighbor of Peter Vranchev, in whose apartment the Communist leaders - Dobri Terpeshev, Anton Yugov, Georgi Chankov, Angel Tsanev, and Katya Avramova were at the time. The coup began at 2 a.m. on 9 September with the seizure of the War Ministry building. War Minister Ivan Marinov sided with the coup and issued the appropriate orders to the First Infantry Division and the School for Reserve Officers.
The jacket harness, also known as AR vest, is a waistcoat (vest) style garment with strong adjustable webbing straps which are adjustable and securely buckled over the shoulders, across the chest and waist, and through the crotch or around each thigh, so that the diver can not slide out under any predictable circumstance. The harness is fitted with several heavy duty D-rings, fixed to the webbing in such a way that the full weight of the diver and all their equipment can be safely supported. A minimum strength for a safe working load of 500 kgf is recommended or required by some codes of practice. A jacket harness is usually provided with webbing straps or a cloth pocket on the back to support the bailout cylinder, may have a variety of pockets to carry tools, and may also carry ditchable or fixed main weights. There are usually several strong D-rings to secure the umbilical and other equipment.
In 2005, Katja Seipel and Volker Schmid suggested that cnidarians and ctenophores are simplified descendants of triploblastic animals, since ctenophores and the medusa stage of some cnidarians have striated muscle, which in bilaterians arises from the mesoderm. They did not commit themselves on whether bilaterians evolved from early cnidarians or from the hypothesized triploblastic ancestors of cnidarians. Resolving the evolutionary relationships within Cnidaria has also been challenging, with almost every possible combination of clades being proposed. As time went on though, a semi-consensus has started to emerge. The enigmatic Polypodium hydriforme and subphylum Myxozoa have been firmly placed within the Cnidaria and have been shown to be closely related to the Medusozoa. In addition, these two groups have been found to likely be each other's closest relatives which, if true, would form the clade "Endocnidozoa". The relationships within the Medusozoa are currently probably the most contentious part of the tree. Traditionally, the class Scyphozoa also included Staurozoa and Cubozoa, but significant morphological differences eventually lead to the split of the three. The group containing them has since been named "Acraspeda". The relationships between these three and Hydrozoa have since and still are debated. A relationship between Scyphozoa and Cubozoa with Staurozoa as its sister has seen support in nearly all studies, but the position of the remaining class, Hydrozoa, is not understood.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.